Adaptive Biotechnologies Corp Cash And Cash Equivalents At Carrying Value

Quick Answer

Adaptive Biotechnologies Corp reported Cash And Cash Equivalents At Carrying Value of $70.50 million for the year ending 2025.

  • Adaptive Biotechnologies Corp showed an increase of +47.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Adaptive Biotechnologies Corp's Cash And Cash Equivalents At Carrying Value has grown by 28.1%.
  • Historical annual values: Fiscal year 2025: $70.50 million | Fiscal year 2024: $47.92 million | Fiscal year 2023: $65.06 million | Fiscal year 2022: $90.03 million | Fiscal year 2021: $139.07 million | Fiscal year 2020: $123.44 million | Fiscal year 2019: $96.58 million | Fiscal year 2018: $55.03 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: